Benitec Biopharma Inc.
No SEC Form 4 filings for $BNTC in the last 30 days.
See all $BNTC insider activity →Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all thre
-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...
HAYWARD, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BNTC (Benitec Biopharma Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BNTC coverage spans financial news and earnings.
Positive interim trial outcomes and cash runway may support short‑term price support, though ongoing net loss tempers upside.
Benitec Biopharma's recent FDA Fast Track designation and positive interim clinical results suggest potential for significant stock appreciation in the near term.
As the issuer of the stock offering, BNTC's stock may experience slight dilution effects; however, the low relevance score suggests this is not a major immediate concern.
The announcement of positive interim clinical results and FDA fast track status for BB-301 is likely to have a positive impact on BNTC's stock, potentially leading to short-term price appreciation.
The appointment of Dr. Sharon Mates to Benitec Biopharma's board signals potential strategic shifts and increased credibility, which could positively influence investor sentiment.
AlphAI scores every news story that mentions BNTC with an AI model for sentiment and relevance, and aggregates insider trades from Benitec Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Benitec Biopharma Inc. (BNTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all thre
2 min read-Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...
3 min readHAYWARD, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference ( "ddRNAi" ) ...
3 min readBB-301 has also been granted Orphan Drug Designation from both FDA and EMA Following the administration of BB-301, Cohort 1 patients experienced significant continuing reductions in dysphagic symptom burden, post-swallow residue accumulation, time required to consume fixed volumes of liquid, and ...
2 min readHAYWARD, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ( ...
2 min readInvestor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST ...
2 min readHAYWARD, Calif., Nov. 02, 2025 ( GLOBE NEWSWIRE ) -- Benitec Biopharma Inc. ( NASDAQ:BNTC ) ( "Benitec" or the "Company" ) , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA ...
2 min readInterim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in ...
3 min readHere is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
3 min readIf you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2 min read
